Analysis of the Clinicopathological Characteristics of Gastric Cancer in Extremely Old Patients.
- Author:
Il Woong SOHN
1
;
Da Hyun JUNG
;
Jie Hyun KIM
;
Hyun Soo CHUNG
;
Jun Chul PARK
;
Sung Kwan SHIN
;
Sang Kil LEE
;
Yong Chan LEE
Author Information
- Publication Type:Original Article
- Keywords: Oldest old; Aged; Stomach neoplasms; Therapy
- MeSH: Aged, 80 and over; Classification; Comorbidity; Humans; Korea; Mortality; Multivariate Analysis; Prognosis; Stomach Neoplasms*; Survival Rate
- From:Cancer Research and Treatment 2017;49(1):204-212
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Gastric cancer is the third-leading cause of cancer-related death in Korea. As the Korean population is ageing, the number of extremely old patients with this disease is increasing. This study examined the clinicopathological characteristics of gastric cancer in extremely old (over 85 years) patients who received treatment or conservative observations and compared the treatment outcomes according to the treatment modality. MATERIALS AND METHODS: A total of 170 patients over 85 years of age were diagnosed with gastric cancer. Of these, 81 underwent treatment for gastric cancer and 89 received conservative observations. The clinicopathological characteristics of the treatment and conservative groupswere compared. RESULTS: The mean age of the patients was 86.5 years. The conservative group included significantly more patients with older ages, macroscopically advanced cancer and upper-middle located cancer. The overall survival rate of the treatment group was significantly higher than that of the conservative group. The disease-specific mortality rate was significantly lower in the treatment group than in the conservative group. Multivariate analysis revealed the clinical course, alarm sign, and macroscopic classification to be independent prognosis factors. CONCLUSION: By itself, the chronological age should not be used as a strategy to determine whether treatmentwill be administered for gastric cancer. Patients who have early gastric cancer or lower-risk preexisting comorbidities should not be discouraged from treatment, even if they are older than 85 years.
